Please login to the form below
rheumatoid arthritis
This page shows the latest rheumatoid arthritis news and features for those working in and with pharma, biotech and healthcare.
Novartis’ Mayzent and Roche’s Polivy lead CHMP recommendations
Also receiving a recommendation for restriction is Pfizer’s rheumatoid arthritis medication Xeljanz (tofacitinib), after the EMA concluded that it could increase the risk of blood clots in the lungs and
Latest news
-
Teva names new CFO and bulks up its opioid liability fund
rheumatoid arthritis, Teva and Celltrion’s drug is expected to make quick headway in the market thanks to a 10% discount on Rituxan’s list price.
-
Pfizer raises forecast following growth of biopharma business
Aside from its oncology business, Pfizer also saw growth of its global revenues for Xeljanz to $599m due to continued volume growth in the rheumatoid arthritis indication and the recent launch ... for psoriatic arthritis in the US.
-
Gilead promotes Andrew Dickinson to CFO, increased M&A expected
One of these potential blockbusters is JAK1 inhibitor filgotinib, which recently reported new, long-term phase 3 clinical data in rheumatoid arthritis.
-
Gilead poaches Genentech-exec Merdad Parsey for its new CMO
Gilead has also bolstered its pipeline with the experimental JAK1 inhibitor filgotinib for rheumatoid arthritis. ... The Galapagos-partnered drug is due to be launched in 2020, and the drug was just filed with regulatory authorities in Japan for the
-
Novartis expands its generics franchise with natalizumab biosimilar
competition. Despite Sandoz gaining approval in 2016for erelzi, its biosimilar version of the rheumatoid arthritis drug, it has been unable to introduce the drug due to the ongoing patent litigation.
More from news
Approximately 56 fully matching, plus 419 partially matching documents found.
Latest Intelligence
-
European biotech: a new generation of leaders emerges
is its experimental JAK1 inhibitor filgotinib for rheumatoid arthritis.
-
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019
Upadacitinib, from AbbVie, treats rheumatoid arthritis. Upadacitinib is an orally dosed inhibitor of an intracellular target called JAK1. ... Dysfunction in the regulation of the JAK family of molecules is implicated in the aberrant production of
-
Drug launches to watch in 2019
It also unveiled mid-stage data on its JAK1 inhibitor upadacitinib in atopic dermatitis, adding another clinical win to earlier successes in rheumatoid arthritis. ... AbbVie has five trials on the go in rheumatoid arthritis and will be filing in that
-
Finding the patient voice
rheumatoid arthritis, oncology, psychiatry, cardiovascular diseases, rare diseases etc.
-
The tipping point
In chronic diseases such as rheumatoid arthritis and inflammatory bowel disease, there are significantly greater savings from switching patients compared with initiating biosimilars in naïve patients alone.
More from intelligence
Approximately 0 fully matching, plus 36 partially matching documents found.
Latest appointments
-
Portland Health appoints Jamie Hewitt as an account director
He joins the firm from the National Rheumatoid Arthritis Society, where he was its head of government affairs, leading the policy and public affairs functions. ... During his time at the National Rheumatoid Arthritis Society, Hewitt ran UK campaigns to
-
Liberation Unlimited promotes Vicky Smith
oncology, rheumatoid arthritis and eye health.
-
Galapagos appoints Bart Filius as chief financial officer
His vast experience in big pharma and his sharp strategic view will help us bring Galapagos to the next level, as we prepare to have our rheumatoid arthritis molecule GLPG0634 enter
-
TiGenix appoints Dr Marie Paule Richard
In her new role Richard will be responsible for the development of several products in Europe and the US, including rheumatoid arthritis and severe sepsis candidate Cx611 and Cx601, which is
-
Liberation promotes Danielle Smith to account director
Meanwhile, Vicky joined Liberation last year and in her new role will continue to work across a range of therapeutic areas including men's health, rheumatoid arthritis and eye health.
More from appointments
Approximately 1 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
RWE Blog 1: Real-world challenges and real-world data
Studies in other disease areas, including rheumatoid arthritis, diabetes and psoriasis, support the idea that using products in the real world is different to that in clinical studies.
-
Infographic: Rheumatoid arthritis (RA)
An overview of the RA biologic patient. Our RA market snapshot offers an introduction to the real world patient data collected by our Therapy Watch RA study. The snapshot looks at twelve of the key indices captured in Therapy Watch data. Click here
-
Webcast: Navigating new frontiers: Ways to find space in the future RA market
In partnership with pharmaphorum. Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case for much longer, as several
-
Report: Living With Rheumatoid Arthritis 2019 reports now available to purchase
We have published new Living with Rheumatoid Arthritis reports in 5EU, Japan and Canada.
-
Report: Living with RA (EU, Japan and Canada) 2019 reports
Research Partnership launches new patient Living with Rheumatoid Arthritis (EU &Japan) 2019 report. ... The qualitative interviews will be enhanced with insights generated from pre-interview patient exercises – such as patient diary entries - to
More from PMHub
Approximately 8 fully matching, plus 17 partially matching documents found.
Featured jobs
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Senior / Principal Medical Writer – Medical Education - UK &...
-
Excellent Salary and Benefits on offer
- Graduate / Entry Level Opportunities – Medical Communications – ...
-
Highly Competitive Remuneration Package
- Experienced / Senior Medical Writer - MedComms - Cardiff - Wales
-
Excellent Salary and Benefits on offer
- Scientific Director - Medical Communications Agency - New York
-
Excellent Remuneration Package
-
Senior Medical Writer
-
Salary TBC
- Senior Medical Writer – Leading Medical Communications Agency – ...
-
Highly Competitive Remuneration Package
-
Account Director, Medical Education
-
Salary TBC
- Scientific Director - Medical Education - Cheshire & London ...
-
Excellent Remuneration Package
Subscribe to our email news alerts
- Genital herpes vaccine candidate heads for human studies
- Sanofi narrows focus, shedding diabetes and cardiovascular research
- Novartis strengthens case for its combination asthma drug
- Biogen defends aducanumab filing plan amid scepticism
- Armed with new data, BMS plans filings for Celgene CAR-T liso-cel
- PMEA 2019 Winners Gallery - PMEA
- Intec battered as Novartis ducks out of Accordion collaboration
- J&J appeals Oklahoma opioid verdict, claiming ‘errors’ in trial
- Sanofi narrows focus, shedding diabetes and cardiovascular research
- Correvio crumbles as FDA panel rejects AFib drug
- BMS’ oral maintenance therapy boosts survival in AML patients
- Sanofi’s sutimlimab set for filing in rare autoimmune anaemia next year
PMHub
Hanson Zandi
Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...
Latest intelligence
- The 2019 CPhI Pharma Index Report
- Examining this year’s industry performance...
- Five key trends in precision and personalised healthcare
- Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
- OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
- Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...
Quick links
Infographics
